TABLE 3.
Per-Lesion Response to Treatment Showing Change in Outcome Measures from Baseline to 6 Week Follow Up
| Lesion | 1.1 | 1.2 | 1.3 | 1.4 | 1.5 | 1.6 | 2.1 | 3.1 | 3.2 | 3.3 | 4.1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Location | Lung | Adrenal | LN | Peritoneum | Bone | Peritoneum | Pleural | Skin | Skin | Skin | Lung |
| Response to treatment | |||||||||||
| 6-week FLT-PET | PR | PR | PR | PR | PR | PR | PD | SD | SD | SD | PR |
| Best overall response | CR | CR | CR | CR | CR | CR | PD | SD | SD | SD | PR |
| Baseline FLT-PET | |||||||||||
| Uptake | |||||||||||
| SUV max | 4.62 | 6.81 | 6.14 | 4.61 | 12.1 | 5.44 | 5.23 | 8.39 | 6.43 | 7.55 | 5.94 |
| SUV peak | 3.69 | 5.39 | 4.99 | 2.86 | 9.71 | 3.66 | 3.92 | 7.41 | 5.26 | 4.97 | 4.84 |
| SUV mean | 2.55 | 3.89 | 3.93 | 2.66 | 7.33 | 3.26 | 2.76 | 5.62 | 3.77 | 4.69 | 3.88 |
| SUV SD | 0.56 | 1.05 | 0.88 | 0.74 | 1.79 | 0.88 | 0.52 | 1.24 | 0.93 | 1.2 | 0.78 |
| Tumor Burden | |||||||||||
| TLP | 64.9 | 26.1 | 61.7 | 4.95 | 60.3 | 7.58 | 353.27 | 288.7 | 50.51 | 9.62 | 102.31 |
| PTV | 25.5 | 6.7 | 15.7 | 1.86 | 8.2 | 2.32 | 128.11 | 51.34 | 13.38 | 2.05 | 26.36 |
| 6-week FLT-PET | |||||||||||
| Uptake | |||||||||||
| Delta-SUV max | −35% | −100% | −67% | −100% | −100% | −100% | 233% | −14% | −48% | −30% | −40% |
| Delta-SUV peak | −32% | −100% | −64% | −100% | −100% | −100% | 295% | −15% | −53% | −15% | −53% |
| Delta-SUV mean | −31% | −100% | −64% | −100% | −100% | −100% | 207% | −19% | −52% | −27% | −51% |
| Delta-SD | −25% | −100% | −74% | −100% | −100% | −100% | 340% | −23% | −52% | −23% | −58% |
| Tumor Burden | |||||||||||
| Delta-TLP | −71% | −100% | −95% | −100% | −100% | −100% | 8690% | 87% | −71% | 27% | −85% |
| Delta-PTV | −59% | −100% | −87% | −100% | −100% | −100% | 2757% | 133% | −40% | 74% | −70% |